Lantheus Holdings, Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-03-17: Measure Net Revenue.
- 2023-03-17: Measure Bonus EPS.
- 2023-03-17: Measure rTSR versus the S&P 600 Health Care Index.
- 2024-03-15: Measure Net Revenue.
| Proxy filed | Measure |
|---|---|
| 2023-03-17 | Net Revenue |
| 2023-03-17 | Bonus EPS |
| 2023-03-17 | rTSR versus the S&P 600 Health Care Index |
| 2024-03-15 | Net Revenue |
| 2024-03-15 | Bonus EPS |
| 2024-03-15 | Relative Total Shareholder Return |
| 2025-03-21 | Net Revenue |
| 2025-03-21 | Bonus EPS |
| 2025-03-21 | rTSR |
| 2026-03-20 | Net Revenue |
| 2026-03-20 | Bonus EPS |
| 2026-03-20 | rTSR |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |